DOCSLIB.ORG

Dr Malcolm A. Trail

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Dr Malcolm A. Trail DR MALCOLM ADAMS TRAILL By Application for Review dated 20 October 2005 and filed with the Victorian Civil and Administrative Tribunal (“VCAT”) on that date, Dr Malcolm Adams Traill seeks to review the determination of a Panel of the Medical Practitioners Board of Victoria made on 19 October 2005 that his registration as a medical practitioner be cancelled, effective from 5:00pm 26 October 2005, and he be disqualified from applying for registration for a period of three years from that date. On 28 October 2005, the VCAT ordered that the operation of the determination be stayed pending final determination of the Application for Review, upon Dr Traill undertaking to the Tribunal not to: A. treat any patient with any form of hyperthermia or 434 mghz microwave therapy; B. hold himself out as an oncologist; C. treat any patient with any form of chemotherapy. The Application for Review is to be fixed for hearing on a date not before 1 April 2006. The Reasons for Decision of the Panel of the Board follow this page. 2 MEDICAL PRACTITIONERS BOARD OF VICTORIA Re: Dr Malcolm Adams Traill [2006] MPBV 1 Reasons for Decision Before: Dr G D Kerr (Chair) Dr Q De Zylva Ms K Sanders Ms A Dea Appearances: Assisting the Panel: Mr C O’Neill of Counsel instructed by Minter Ellison, Lawyers For the Practitioner: In person Dates of Hearing: 26, 27 & 28 April 2005, 18 & 19 July 2005, 17 & 19 October 2005 Date of Decision: 19 October 2005 Findings: 1. Dr Traill engaged in unprofessional conduct within the meaning of paragraphs 3(1)(a) and/or 3(1)(b) and/or 3(1)(c) and/or 3(1)(e) of the definition of "unprofessional conduct" in the Medical Practice Act 1994 (“the Act”) in that, during the period on or about 23 September 2000 to 27 November 2000, he failed to exercise the care and skill of a competent medical practitioner in his treatment of his patient, Ms SO, who was diagnosed in August 2000 with small cell carcinoma of the lung; 2. Dr Traill engaged in unprofessional conduct within the meaning of paragraphs 3(1)(a) and/or 3(1)(b) and/or 3(1)(c) and/or 3(1)(e) of the definition of "unprofessional conduct" in the Act, in that between 22 January and 9 February 2001, he failed to exercise the care and skill of a competent medical practitioner in his treatment of his patient, Ms ST, who suffered from recurrent cutaneous metastatic breast cancer of the right breast; and 3. Dr Traill engaged in unprofessional conduct within the meaning of paragraphs 3(1)(a) and/or 3(1)(b) and/or 3(1)(c) and/or 3(1)(e) of the definition of "unprofessional conduct" in the Act, in that during the period on or about October 3 and November 2001, he failed to exercise the care and skill of a competent medical practitioner in his treatment of his patient, Master TU, a five-year-old child with a malignant brain tumour, a widely disseminated anaplastic ependymoma; and 4. That unprofessional conduct was of a serious nature pursuant to section 45A(1)(a) of the Act. Determinations 1. The unanimous determination of the Panel is that Dr Traill is reprimanded for his conduct pursuant to section 45A(2)(c) of the Act. 2. Further the Panel (by majority, Dr De Zylva dissenting) has determined that Dr Traill’s registration is to be cancelled pursuant to section 45A(2)(h) of the Act and that cancellation is to come into effect at 5 pm on Wednesday, 26 October 2005. The majority also determined pursuant to section 45A(2)(i) of the Act that Dr Traill is disqualified from applying for registration under section 5 of the Act for a period of three years. 4 Reasons for Decision The Medical Practitioners Board of Victoria (“the Board”) determined under section 46 of the Medical Practice Act 1994 (“the Act”) that a Formal Hearing was to be held into the professional conduct of Dr Traill. A Panel was convened and the hearing was held on 26, 27 & 28 April 2005, 18 & 19 July 2005 and 17 & 19 October 2005. The allegations heard by the Panel were contained in an Amended Notice of Formal Hearing (“Notice”). The Panel was required to determine whether Dr Traill: “1. engaged in unprofessional conduct within the meaning of paragraphs 3(1)(a) and/or 3(1)(b) and/or 3(1)(c) and/or 3(1)(d) and/or 3(1)(e) of the definition of "unprofessional conduct" in the Act, in that: (a) During the period on or about 23 September 2000 to 27 November 2000, [he] failed to exercise the care and skill of a competent medical practitioner in [his] treatment of [his] patient, Ms SO, who was diagnosed in August 2000 with small cell carcinoma of the lung. Particulars (i) On or about 23 September 2000, [he] recommended to [his] patient a treatment called full body hyperthermia treatment, which treatment was not beneficial or effective for a patient with potentially curable cancer; (ii) [He] failed to provide [his] patient with adequate information to obtain her informed consent to the treatment, including [his] failure to advise her that her withdrawal from the planned chemotherapy cycles could adversely effect her health and prognosis and that the most efficacious treatment for her cancer was cytoxic chemotherapy and thoracic radiation; (iii) [He] provided UHF 434 Mghz microwave therapy treatment for [his] patient, which treatment was not beneficial nor effective for a patient with potentially curable cancer; (iv) [He] charged the Health Insurance Commission for 15 professional services for item 13915, cytoxic chemotherapy, intravenous (less than one hour) but did not administer this treatment to [his] patient at all; (v) On or about 5 October 2000 until the end of October 2000, [he] prescribed lithium to the patient, an experimental treatment, administered under [his] knowledge and 5 supervision, that was unnecessary or not reasonably required in the treatment of [his] patient; (vi) [He] failed to monitor the level of lithium in the patient's blood; (vii) [He] charged [his] patient a sum of between $6,500 - $7,000 for [his] treatment of the patient which did not attract any Medicare rebate, which in the circumstances of the patient was excessive; (viii) [He] failed to adequately follow up [his] treatment of [his] patient; (ix) [He] claimed to the patient to be an oncologist, but [he] did not have any formal oncology qualification or recent oncologic training; (x) [He] failed to adequately monitor [his] patient during [his] treatment in so far as [he] monitored the effect of [his] treatment by testing the patient's uric acid levels, such methodology having no support in the small lung cell literature. Further, until requested by the patient, [he] did not request CT scans or undertake adequate x-ray investigation of [his] patient; and (xi) By pursuing an ineffective and time consuming treatment the patient was denied proper medical advice and a potential cure. (b) Between 22 January and 9 February 2001, [he] failed to exercise the care and skill of a competent medical practitioner in [his] treatment of [his] patient, Ms ST, who suffered from recurrent cutaneous metastatic breast cancer of the right breast: Particulars (i) [He] recommended treatment of her condition with microwave hyperthermia and local hyperthermia treatment; (ii) [He] failed to provide the patient with adequate information to obtain her informed consent to the treatment; (iii) Further, [he] provided her with 15 UHF 434 Mghz hyperthermia treatments and 15 local hyperthermia treatments, in circumstances where the treatment was an ineffective, unproven mode of treatment for the patient's condition; (iv) [He] failed to forward records of [his] treatment of the patient, when requested by her treating surgeon in Tasmania in a 6 timely manner. Dr Linacre requested information from [him] on 5 January 2001 and [he] replied to [Dr Linacre] on 29 March 2001; (v) [He] failed to investigate and diagnose lesions on the skin over [the] Ms ST's right breast at the time of providing the treatment to her; (vi) [He] failed to obtain a biopsy and histology of the lesions; (vii) [He] charged the patient the sum of $10,734.85 for treatment which in the circumstances, was excessive; and (viii) [He] billed the Health Insurance Commission for item 13915 for the patient on the following dates: 22 - 26 January 2001, 29 [January] - 2 February 2001 and 5 - 9 February 2001 for cytotoxic chemotherapy, administration, either by intravenous push or intravenous infusion but did not provide the patient with such chemotherapy treatment. (c) During the period on or about October and November 2001, [he] failed to exercise the care and skill of a competent medical practitioner in [his] treatment of [his] patient, TU, a five-year-old child with a malignant brain tumour, a widely disseminated anaplastic ependymoma. Particulars (i) [He] recommended treatment of TU's condition with UHF 434 Mghz treatment, a form of treatment that has not been demonstrated to be efficacious for such a condition; (ii) By providing this treatment [he] potentially interfered in the treating relationship between TU and his parents and Dr Peter Downie, TU’s treating oncologist; (iii) By providing this treatment [he] interfered in the clinical management of TU’s condition at the Royal Children's Hospital; and (iv) [He] provided treatment without informing, consulting or involving TU's treating oncologist.” The definitions of “unprofessional conduct” contained in section 3(1) of the Act relevant to the Notice are as follows; “(a) professional conduct which is of a lesser standard than that which the public might reasonably expect of a registered medical practitioner; or (b) professional conduct which is of a lesser standard than that which might reasonably be expected of a medical practitioner by her or his 7 peers; or (c) professional misconduct; or (d) infamous conduct in a professional respect; or (e) providing a person with health services of a kind that is excessive, unnecessary or not reasonably required for that person’s well-being;” Amendment of the Notice In his written submission Dr Traill stated that he had been denied natural justice because the Notice had been amended at the end of the five day hearing of evidence and oral submissions and after witnesses had provided testimony and been cross examined.
Load more

Recommended publications
  • Biomedical Engineering for Africa
    Biomedical Engineering for Africa Edited by Tania S. Douglas q Biomedical Engineering for Africa This work is licenced under the Creative Commons license: © The Authors Published in 2019 by University of Cape Town Libraries, Rondebosch, Cape Town, 7700, South Africa. Suggested citation: Douglas, T.S. Ed. 2019. Biomedical engineering for Africa. Cape Town: University of Cape Town Libraries. DOI: http://dx.doi.org/10.15641/0-7992-2544-0 Suggested citation of a chapter: Makobore, P.N. & Mulerwa, M. 2019. An electronically controlled gravity feed infusion set for intravenous fluids. In Biomedical engineering for Africa. T.S. Douglas, Ed. Cape Town: University of Cape Town Libraries. 125–138. DOI: http://dx.doi.org/10.15641/0-7992-2544-0 ISBN: 978-0-7992-2544-0 Contents List of Contributors v Foreword ix Folasade T. Ogunsola Chapter 1. Introduction 1 T.S. Douglas and R.L. Murphy Part 1. African Perspectives on Biomedical Engineering 5 Chapter 2. The Case for Biomedical Engineers in African Hospitals: A Clinician’s Point of View 7 D. Atwine Chapter 3. Recent Developments in Biomedical Engineering Education in Africa: A Focus on Nigeria and the University of Ibadan 11 A. Coker, F. Akintayo, C. Achi, M. Odeniyi, A. Olorunnisola and D. Akano Chapter 4. Creating a Department of Biomedical Engineering and an Undergraduate Programme – The University of Lagos Experience 19 O.P. Popoola, N.K. Irurhe, O.J. Balogun and A.A. Osuntoki Chapter 5. Biomedical Engineering in Ethiopia 27 A. Hussein and D. Assefa Part 2. From Needs to Products 33 Chapter 6. Biomedical Engineering and Entrepreneurship 35 C.J.
    [Show full text]
  • Patient Information Brochure
    2018/01/10 Dear Patient Welcome to our practice. We trust that you will find a supportive and caring environment with us. We would like to take the opportunity to introduce you to our staff, facilities, services and procedures with this brochure. STAFF Oncologists: We have six experienced specialists in our partnership: • Dr Rory Callaghan - The founding partner of the practice. He practices in Durban and Umhlanga, Ballito and in Hillcrest. Contact details: Office: 031-209 9030 (Durban), 031-350 4011 (Umhlanga), 031-350 4060 (Hillcrest) Cellular phone: 083-775 9154 email: [email protected] • Dr Leon Marais - He practices in Hillcrest and Durban. Contact details: Office: 031-209 9030 (Durban), 031-350 4060 (Hillcrest) Cellular phone: 083-636 6666 email: [email protected] • Dr Neil Narsai - He practices in Umhlanga and Durban. Contact details: Office: 031-209 9030 (Durban), 031-350 4011 (Umhlanga) Cellular phone: 081-016 4196 email: [email protected] • Dr Anne Maxwell - She practices in Durban. Contact details: Office: 031-209 9030 (Durban) Cellular phone: 083-789 5548 email: [email protected] • Dr Ria David – She practices in Durban and Umhlanga Contact details: Office: 031-209 9030 (Durban), 031-350 4011 (Umhlanga) Cellular phone: 083-682 0038 email: [email protected] • Dr Poovan Govender – He practices in Durban and Umhlanga Contact details: Office: 031-209 9030 (Durban), 031-350 4011 (Umhlanga) Cellular phone: 083-775 3255 email: [email protected] We value the relationship between us and our patients. Although you will mostly be seeing the same doctor, there will be times when the that doctor is not available.
    [Show full text]
  • Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT
    Genitourinary Imaging • Original Research Smith et al. Size and Attenuation of Metastatic RCC on CECT Genitourinary Imaging Original Research Assessing Tumor Response and Detecting Recurrence in Metastatic Renal Cell Carcinoma on Targeted Therapy: Importance of Size and Attenuation on Contrast-Enhanced CT Andrew Dennis Smith1 OBJECTIVE. The aim of this study was to improve response assessment in patients with Michael L. Lieber metastatic renal cell carcinoma (RCC) on antiangiogenic targeted therapy by evaluating Shetal N. Shah changes in both tumor size and attenuation and by detecting unique patterns of contrast en- hancement on contrast-enhanced CT (CECT). Smith AD, Lieber ML, Shah SN MATERIALS AND METHODS. Tumor long-axis measurements and volumetric mean tumor attenuation of target lesions on CECT images were correlated with time to progression in 53 patients with metastatic clear cell RCC treated with first-line sorafenib or sunitinib. The frequencies of specific patterns of tumor progression were assessed. The data were used to develop new imaging criteria, the size and attenuation CT (SACT) criteria. CECT findings were evaluated using the SACT criteria, Response Evaluation Criteria in Solid Tumors (RE- CIST), and modified Choi criteria, and the Kaplan-Meier method was used to estimate sur- vival functions. RESULTS. One or more target metastatic lesions had decreased attenuation of ≥ 40 HU in 59% of patients with progression-free survival of > 250 days (n = 44) after initiating targeted therapy; 0% of patients with earlier disease progression (n = 9) had this finding. A favorable response based on SACT criteria had a sensitivity of 75% and specificity of 100% for identify- ing patients with progression-free survival of > 250 days, versus 16% and 100%, respectively, for RECIST and 93% and 44% for the modified Choi criteria.
    [Show full text]
  • Europe's Beating Cancer Plan
    EUROPEAN COMMISSION Brussels, 3.2.2021 COM(2021) 44 final COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT AND THE COUNCIL Europe's Beating Cancer Plan {SWD(2021) 13 final} EN EN CONTENTS 1. A Cancer Plan for Europe: Introduction .................................................................................. 2 2. A modern approach to cancer: new technologies, research and innovation at the service of patient-centred cancer prevention and care ..................................................................................... 4 2.1. Driving change through knowledge and research ............................................................ 4 2.2. Making the most of data and digitalisation in cancer prevention and care ...................... 5 3. Saving lives through sustainable cancer prevention ................................................................ 7 3.1. Improving health literacy on cancer risks and determinants ............................................ 8 3.2. Achieving a tobacco-free Europe ..................................................................................... 8 3.3. Reducing harmful alcohol consumption .......................................................................... 9 3.4. Improving health promotion through access to healthy diets and physical activity ...... 10 3.5. Reducing environmental pollution ................................................................................. 11 3.6. Reducing exposure to hazardous substances and radiation ...........................................
    [Show full text]
  • Adolescent and Young Adult Cancer Survival Guide
    ADOLESCENT AND YOUNG ADULT CANCER SURVIVAL GUIDE FEATURING: LEONARD SENDER, MD & HEATHER HAWTHORNE, MD JUNE 2015 Watch the AYA Cancer Survival Guide Video INTRODUCTION The Hyundai Cancer Institute at CHOC Children’s Adolescent and Young Adult (AYA) Cancer Survival Guide Every year 70,000 young adults aged 15-39 are diagnosed with cancer in the United States alone. The CHOC Children’s Adolescent and Young Adult (AYA) Cancer Survival Guide Video and eBook are designed to help you face the challenges of your diagnosis, phase by phase. This CHOC Children’s AYA Cancer Survival Guide eBook supports you in setting measurable and achievable health goals, empowering you to become fully engaged in your journey from diagnosis to wellbeing. Whether you are a patient, caregiver or healthcare professional, this Survival Guide Video and eBook provide the expert insight, knowledge and information you need to make informed decisions. The Survival Guide eBook is interactive and serves as a creatively driven resource developed to help you, along with your family and support network as you engage with your doctors and healthcare providers. • Take your eBook with you to your appointments and treatments. • Use it to help you focus and optimize the treatment plan you elect to pursue. CHOC Children’s is dedicated to helping you survive and thrive. Thank you for selecting the CHOC Children’s AYA Cancer Survival Guide Video and eBook to accompany your journey from diagnosis to wellbeing. iii TABLE OF 1. Introduction CONTENTS 2. Advice for Using This AYA Cancer Survival Guide eBook 3. Dr. Leonard Sender, MD Introduction Introducing Dr.
    [Show full text]
  • Oncothermia Journal, May 2013 1
    2 A publication of Oncotherm June 2013 Volume 7 ISSN 2191-6438 OONNCCOOTTHHEERRMMIIAA JJOOUURRNNAALL Abstracts of the XXXI. Conference of the International Clinical Hyperhtermia Society (ICHS) Posters of the XXXI. Conference of the International Clinical Hyperthermia Society (ICHS) www.Oncothermia-Journal.comOncothermia Journal, May 2013 1 Editorial Dear Reader, at the end of last year we presented you a great variety of abstracts for talks and posters that were presented at the XXXI. Conference of the ICHS (International Clinical Hyperthermia Society) jointly held with the 2nd International Oncothermia Symposium. This large event – Oncotherm was the main sponsor -was held from October 12th-14th in Budapest, Hungary. Around 150 professors, doctors and experts from various disciplines came together representing 25 countries from all over the world in the beautiful Marriott Hotel, situated directly at the Danube. The proceedings of the conference with extended abstracts and some complete papers of the conference will be published in a peer-reviewed open-access journal: The „Conference Papers in Medicine“ very soon. In this issue of the Oncothermia Journal we are showing you the posters of the conference in the form as they were presented. New president and directors of ICHS were elected in Budapest. Prof. Dr. Clifford L.K. Pang became the new president and will host this year’s conference in Guangzhou, China from November 8th-10th, 2013. You can find more information about the ICHS and its structure in this magazine. We are pleased to learn about Oncotherm’s international success. However, our roots are in Germany. The smart German medical approach is still in our focus and is very important for the development of this method.
    [Show full text]
  • 2020-08-0852 TT ACF Onchronicle Newsletter 7.4Mb
    Issue 01 Vol 01 August 2020 OnChronicleC AN EXCLUSIVE NEWSLETTER OF ALAMELU CHARITABLE FOUNDATION, SUPPORTED BY TATA TRUSTS 1 Assam Cancer Care Foundation, a joint initiative of Government of Assam and Tata Trusts, is the Welcome most significant arm of the programme – with 10 under-construction hospitals and multiple operational projects, some of which are first of Note their kind. The state of Assam, which reports 32,000 new Dear Reader cancer cases every year, of which 70% of cases are reported in later stages, needed a structured We are delighted to bring you the first volume and early detection and screening programme. issue of ONCHRONICLE, the exclusive newsletter Through an MOU with National Health Mission of Alamelu Charitable Foundation (ACF), (NHM), capacity building, screening for early supported by Tata Trusts. detection and awareness programme has been launched in 8 districts. Opportunistic screening ACF was conceived and conceptualised by the kiosks have been opened up in 4 Medical College Tata Trusts in 2017, to mitigate the problems that Hospitals. ail cancer care in India. Since then it has been fighting against the lack of infrastructure and We have also entered into an understanding with trained workforce, deficient diagnostic and NHM in Maharashtra, Jharkhand, Andhra therapeutic medical equipment, limited financial Pradesh and Odisha and the capacity building, access, lack of cancer and palliative awareness, early detection and screening programmes are absence of quality care and more, while being rolled out in respective catchments. encouraging detection of cancer in its early stages. To provide the ease of access to cancer patients Content for chemotherapy and radiotherapy facilities, we To address these issues, the team is working at have introduced novel Day Care Centres.
    [Show full text]
  • Cancer Management During COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful Or Beneficial?
    cancers Review Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial? Silvia Vivarelli 1, Luca Falzone 2,* , Caterina Maria Grillo 3, Giuseppa Scandurra 4, Francesco Torino 5 and Massimo Libra 1,6,* 1 Laboratory of Translational Oncology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy; [email protected] 2 Epidemiology Unit, IRCCS Istituto Nazionale Tumori ‘Fondazione G. Pascale’, I-80131 Naples, Italy 3 Otolaryngology Unit, Department of Medical Sciences, Surgical and Advanced Technologies, University of Catania, 95123 Catania, Italy; [email protected] 4 Medical Oncology Unit, Azienda Ospedaliera Cannizzaro, 95126 Catania, Italy; [email protected] 5 Department of Systems Medicine, Medical Oncology, University of Rome Tor Vergata, 00133 Rome, Italy; [email protected] 6 Research Center for Prevention, Diagnosis and Treatment of Cancer, University of Catania, 95123 Catania, Italy * Correspondence: [email protected] (L.F.); [email protected] (M.L.); Tel.: +39-320-1247-7937 (L.F.); +39-095-478-1271 (M.L.) Received: 8 July 2020; Accepted: 7 August 2020; Published: 10 August 2020 Abstract: The coronavirus disease 2019 (COVID-19) is currently representing a global health threat especially for fragile individuals, such as cancer patients. It was demonstrated that cancer patients have an increased risk of developing a worse symptomatology upon severe acute respiratory syndrome associated coronavirus-2 (SARS-CoV-2) infection, often leading to hospitalization and intensive care. The consequences of this pandemic for oncology are really heavy, as the entire healthcare system got reorganized. Both oncologists and cancer patients are experiencing rescheduling of treatments and disruptions of appointments with a concurrent surge of fear and stress.
    [Show full text]
  • What's Inside
    Newsletter A publication of the Controlled Release Society Volume 34 • Number 4 • 2017 What’s Inside Formulation of Monodisperse Non-Ionic Surfactant Vesicles (NISV) by Microfluidic Mixing Compared to Other Formulation Methods Electrospun Nanofibers for Localized Delivery of Dexamethasone: Preliminary Investigation on Formulation Parameters Controlled Release of Sex Pheromone from Ester Wax/ Polymer Bag Dispenser for Prevention of Grapholita molesta Interview with Arto Urtti Chapter News Newsletter Kenneth Carson Vol. 34 • No. 4 • 2017 Editor > TABLE OF CONTENTS 3 From the Editor 4 From the President Ryan Donnelly 5 2017 Awards & Recognition Editor 8 Interview A Focus on Ocular Delivery: Interview with Arto Urtti 11 Scientifically Speaking Formulation of Monodisperse Non-Ionic Surfactant Vesicles (NISV) by Microfluidic Mixing Compared to Other Formulation Methods Steven Giannos 14 Scientifically Speaking Editor Electrospun Nanofibers for Localized Delivery of Dexamethasone: Preliminary Investigation on Formulation Parameters 17 Scientifically Speaking Controlled Release of Sex Pheromone from Ester Wax/Polymer Bag Dispenser for Prevention of Grapholita molesta 21 Chapter News Medha Joshi Report on the First Joint CRS–CoRE-Net Industry-Academia Networking Day, Editor June 23, 2017 23 Chapter News CRS Nordic Chapter Meeting 25 DDTR Update Drug Delivery and Translational Research Update Arlene McDowell 27 People in the News Editor 29 Companies in the News > ADVERTISER INDEX 20 Millipore Sigma Bozena Michniak-Kohn Editor Cover image: Molecular structure of steroid Dexamethasone – synthetic steriod medication, 3D rendering Raimundo79 / Shutterstock.com Rod Walker Editor 2 > FROM THE EDITOR Editors Kenneth Carson Ryan Donnelly Medha Joshi Steven Giannos Midwestern University, Chicago College of Pharmacy Medha Joshi Downers Grove, IL, U.S.A.
    [Show full text]
  • Zimbabwe: Medical Treatment and Healthcare
    Country Policy and Information Note Zimbabwe: Medical treatment and healthcare Version 2.0 April 2021 Preface Purpose This note provides country of origin information (COI) for decision makers handling cases where a person claims that to remove them from the UK would be a breach of Articles 3 and/or 8 of the European Convention on Human Rights (ECHR) because of an ongoing health condition. It is not intended to be an exhaustive survey of healthcare in Zimbabwe. Country of origin information The country information in this note has been carefully selected in accordance with the general principles of COI research as set out in the Common EU [European Union] Guidelines for Processing Country of Origin Information (COI), dated April 2008, and the Austrian Centre for Country of Origin and Asylum Research and Documentation’s (ACCORD), Researching Country Origin Information – Training Manual, 2013. Namely, taking into account the COI’s relevance, reliability, accuracy, balance, currency, transparency and traceability. The structure and content of the country information section follows a terms of reference which sets out the general and specific topics relevant to this note. All information included in the note was published or made publicly available on or before the ‘cut-off’ date(s) in the country information section. Any event taking place or report/article published after these date(s) is not included. All information is publicly accessible or can be made publicly available, and is from generally reliable sources. Sources and the information they provide are carefully considered before inclusion. Factors relevant to the assessment of the reliability of sources and information include: x the motivation, purpose, knowledge and experience of the source x how the information was obtained, including specific methodologies used x the currency and detail of information, and x whether the COI is consistent with and/or corroborated by other sources.
    [Show full text]
  • Healthcare List of Medical Institutions Participating in Medisave Scheme Last Updated on 1 April 2020 by Central Provident Fund Board
    1 Healthcare List of Medical Institutions Participating in MediSave Scheme Last updated on 1 April 2020 by Central Provident Fund Board PUBLIC HOSPITALS/MEDICAL CLINICS Alexandra Hospital* Admiralty Medical Centre* Changi General Hospital* Institute of Mental Health Jurong Medical Centre* Khoo Teck Puat Hospital* KK Women's And Children's Hospital* National Cancer Centre National Dental Centre National Heart Centre Singapore National Skin Centre National University Hospital* Ng Teng Fong General Hospital* Singapore General Hospital* Singapore National Eye Centre Sengkang General Hospital* Tan Tock Seng Hospital* PRIVATE HOSPITALS/MEDICAL CLINICS Concord International Hospital Farrer Park Hospital Gleneagles Hospital* Mt Alvernia Hospital* Mt Elizabeth Hospital* Mount Elizabeth Novena Hospital Parkway East Hospital* Raffles Hospital Pte Ltd Starmed Specialist Centre Pte Ltd Thomson Medical Centre* PRIVATE CLINIC FOR OUTPATIENT HYPERBARIC OXYGEN THERAPY CLAIM Hyperbaric Medical Services DAY SURGERY CENTRES A Clinic For Women A Company For Women A L Lim Clinic For Women Pte Ltd Abraham’s Ear, Nose & Throat Surgery Pte Ltd Access Medical (Toa Payoh) Access Medical (Bukit Batok) Access Medical (East Coast) Access Medical (Kim Keat) Access Medical (Marine Terrace) Access Medical (Whampoa) Access Medical (Redhill Close) Access Medical (Tampines 730) Access Medical (Circuit Road) Access Medical (Bedok South) *These medical institutions also provide approved Hepatitis B, Pneumococcal and Human Papillomavirus (HPV) vaccinations to their patients.
    [Show full text]
  • Hospitalaria 2021 Mariola Sirvent-Ochando Et Al
    Farmacia Hospitalaria 2021 Mariola Sirvent-Ochando et al. l Vol. 45 l Nº 3 l 109 - 114 l 109 Farmacia HOSPITALARIA Órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria ORIGINALS Author of correspondence Bilingual edition English/Spanish Margarita Garrido Siles Autovía A-7, km 187 NUTRI-ONCOCARE: New integral nutrition care model 29603 Marbella (Málaga). Spain. to prevent and treat malnutrition in cancer patients Email: [email protected] NUTRI-ONCOCARE: Nuevo modelo integral de atención nutricional para prevenir y tratar la desnutrición en pacientes con cáncer Mariola Sirvent-Ochando1, Ana Murcia-López2, Cristina Sangrador-Pelluz3, Sara Esplá1, Margarita Garrido-Siles4, Jimena Abilés4 Received 1 July 2019; 1 2 Servicio de Farmacia Hospitalaria, Clínica Vistahermosa-HLA, Alicante. Spain. Servicio de Farmacia Hospitalaria, Hospital General Universitario de Elche, Elche Accepted 30 March 2020. (Alicante). Spain. 3Servicio de Farmacia Hospitalaria, Hospital Universitario Mutua Terrassa, Terrassa (Barcelona). Spain. 4Servicio de Farmacia y Nutrición, Hospital Costa del Sol, Málaga. Spain. DOI: 10.7399/fh.11299 How to cite this paper Sirvent-Ochando M, Murcia-López A, Sangrador-Pelluz C, Esplá S, Garrido-Siles M, Abilés J. NUTRI-ONCOCARE: New integral nutrition care model to prevent and treat malnutrition in cancer patients. Farm Hosp. 2021;45(3):109-14. Abstract Resumen Objective: The maximum expression of malnutrition in cancer patients Objetivo: La máxima expresión de la desnutrición en los pacientes is cancerous cachexia, always linked to an unfavorable prognosis. Given oncológicos es la caquexia cancerosa, siempre vinculada a un pronóstico its evolutionary nature it is recommended to detect and act early in those desfavorable.
    [Show full text]